In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles

Sai T. Reddy, Annemie Rehor, Hugo G. Schmoekel, Jeffrey A. Hubbell, Melody A. Swartz

Research output: Contribution to journalArticle

375 Citations (Scopus)

Abstract

Delivery of biodegradable nanoparticles to antigen-presenting cells (APCs), specifically dendritic cells (DCs), has potential for immunotherapy. This study investigates the delivery of 20, 45, and 100 nm diameter poly(ethylene glycol)-stabilized poly(propylene sulfide) (PPS) nanoparticles to DCs in the lymph nodes. These nanoparticles consist of a cross-linked rubbery core of PPS surrounded by a hydrophilic corona of poly(ethylene glycol). The PPS domain is capable of carrying hydrophobic drugs and degrades within oxidative environments. 20 nm particles were most readily taken up into lymphatics following interstitial injection, while both 20 and 45 nm nanoparticles showed significant retention in lymph nodes, displaying a consistent and strong presence at 24, 72, 96 and 120 h post-injection. Nanoparticles were internalized by up to 40-50% of lymph node DCs (and APCs) without the use of a targeting ligand, and the site of internalization was in the lymph nodes rather than at the injection site. Finally, an increase in nanoparticle-containing DCs (and other APCs) was seen at 96 h vs. 24 h, suggesting an infiltration of these cells to lymph nodes. Thus, PPS nanoparticles of 20-45 nm have the potential for immunotherapeutic applications that specifically target DCs in lymph nodes.

Original languageEnglish
Pages (from-to)26-34
Number of pages9
JournalJournal of Controlled Release
Volume112
Issue number1
DOIs
StatePublished - May 1 2006
Externally publishedYes

Fingerprint

Nanoparticles
Dendritic Cells
Lymph Nodes
Antigen-Presenting Cells
Injections
Ethylene Glycol
poly(propylene sulfide)
Immunotherapy
Ligands
Pharmaceutical Preparations
propylene sulfide

Keywords

  • Antigen-presenting cells
  • Immunotherapy
  • Macrophages
  • Vaccines

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. / Reddy, Sai T.; Rehor, Annemie; Schmoekel, Hugo G.; Hubbell, Jeffrey A.; Swartz, Melody A.

In: Journal of Controlled Release, Vol. 112, No. 1, 01.05.2006, p. 26-34.

Research output: Contribution to journalArticle

Reddy, Sai T. ; Rehor, Annemie ; Schmoekel, Hugo G. ; Hubbell, Jeffrey A. ; Swartz, Melody A. / In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. In: Journal of Controlled Release. 2006 ; Vol. 112, No. 1. pp. 26-34.
@article{525297209a72449397944abce4fbc3aa,
title = "In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles",
abstract = "Delivery of biodegradable nanoparticles to antigen-presenting cells (APCs), specifically dendritic cells (DCs), has potential for immunotherapy. This study investigates the delivery of 20, 45, and 100 nm diameter poly(ethylene glycol)-stabilized poly(propylene sulfide) (PPS) nanoparticles to DCs in the lymph nodes. These nanoparticles consist of a cross-linked rubbery core of PPS surrounded by a hydrophilic corona of poly(ethylene glycol). The PPS domain is capable of carrying hydrophobic drugs and degrades within oxidative environments. 20 nm particles were most readily taken up into lymphatics following interstitial injection, while both 20 and 45 nm nanoparticles showed significant retention in lymph nodes, displaying a consistent and strong presence at 24, 72, 96 and 120 h post-injection. Nanoparticles were internalized by up to 40-50{\%} of lymph node DCs (and APCs) without the use of a targeting ligand, and the site of internalization was in the lymph nodes rather than at the injection site. Finally, an increase in nanoparticle-containing DCs (and other APCs) was seen at 96 h vs. 24 h, suggesting an infiltration of these cells to lymph nodes. Thus, PPS nanoparticles of 20-45 nm have the potential for immunotherapeutic applications that specifically target DCs in lymph nodes.",
keywords = "Antigen-presenting cells, Immunotherapy, Macrophages, Vaccines",
author = "Reddy, {Sai T.} and Annemie Rehor and Schmoekel, {Hugo G.} and Hubbell, {Jeffrey A.} and Swartz, {Melody A.}",
year = "2006",
month = "5",
day = "1",
doi = "10.1016/j.jconrel.2006.01.006",
language = "English",
volume = "112",
pages = "26--34",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles

AU - Reddy, Sai T.

AU - Rehor, Annemie

AU - Schmoekel, Hugo G.

AU - Hubbell, Jeffrey A.

AU - Swartz, Melody A.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Delivery of biodegradable nanoparticles to antigen-presenting cells (APCs), specifically dendritic cells (DCs), has potential for immunotherapy. This study investigates the delivery of 20, 45, and 100 nm diameter poly(ethylene glycol)-stabilized poly(propylene sulfide) (PPS) nanoparticles to DCs in the lymph nodes. These nanoparticles consist of a cross-linked rubbery core of PPS surrounded by a hydrophilic corona of poly(ethylene glycol). The PPS domain is capable of carrying hydrophobic drugs and degrades within oxidative environments. 20 nm particles were most readily taken up into lymphatics following interstitial injection, while both 20 and 45 nm nanoparticles showed significant retention in lymph nodes, displaying a consistent and strong presence at 24, 72, 96 and 120 h post-injection. Nanoparticles were internalized by up to 40-50% of lymph node DCs (and APCs) without the use of a targeting ligand, and the site of internalization was in the lymph nodes rather than at the injection site. Finally, an increase in nanoparticle-containing DCs (and other APCs) was seen at 96 h vs. 24 h, suggesting an infiltration of these cells to lymph nodes. Thus, PPS nanoparticles of 20-45 nm have the potential for immunotherapeutic applications that specifically target DCs in lymph nodes.

AB - Delivery of biodegradable nanoparticles to antigen-presenting cells (APCs), specifically dendritic cells (DCs), has potential for immunotherapy. This study investigates the delivery of 20, 45, and 100 nm diameter poly(ethylene glycol)-stabilized poly(propylene sulfide) (PPS) nanoparticles to DCs in the lymph nodes. These nanoparticles consist of a cross-linked rubbery core of PPS surrounded by a hydrophilic corona of poly(ethylene glycol). The PPS domain is capable of carrying hydrophobic drugs and degrades within oxidative environments. 20 nm particles were most readily taken up into lymphatics following interstitial injection, while both 20 and 45 nm nanoparticles showed significant retention in lymph nodes, displaying a consistent and strong presence at 24, 72, 96 and 120 h post-injection. Nanoparticles were internalized by up to 40-50% of lymph node DCs (and APCs) without the use of a targeting ligand, and the site of internalization was in the lymph nodes rather than at the injection site. Finally, an increase in nanoparticle-containing DCs (and other APCs) was seen at 96 h vs. 24 h, suggesting an infiltration of these cells to lymph nodes. Thus, PPS nanoparticles of 20-45 nm have the potential for immunotherapeutic applications that specifically target DCs in lymph nodes.

KW - Antigen-presenting cells

KW - Immunotherapy

KW - Macrophages

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=33646480406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646480406&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2006.01.006

DO - 10.1016/j.jconrel.2006.01.006

M3 - Article

VL - 112

SP - 26

EP - 34

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -